Billionaire Israel Englander Increased His Stake In Eli Lilly During the Third Quarter: Should You?
After flying high during the first half of the year, pharmaceutical giant Eli Lilly (NYSE: LLY) has lost some momentum; the ...
'Nuclear Option'?: Eli Lilly Taps Big Law Firms in Federal Drug Pricing Dispute
The Health Resources and Services Administration has “invoked the nuclear option of removal from not only the 340B program ...
Eli Lilly Stock: Unexpected Developments (Rating Downgrade)
Eli Lilly faces challenges with slowing drug sales and a lawsuit against the HRSA. Learn why caution is advised for LLY stock despite its lower P/E ratio.
Yahoo Finance3d
Jim Cramer on Eli Lilly and Company (LLY): ‘I’m Kind Of Blown Away’
In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against Jim Cramer's other stocks. Jim Cramer, the host of Mad Money, recently shared his insights ...
The Motley Fool on MSN3d
Is It Time to Sell Eli Lilly and Pfizer Stocks?
Eli Lilly now ranks as the largest drugmaker in the world based ... Much of Lilly's recent dismal stock performance ...
Eli Lilly and Company: Lilly announces changes on board of directors
Eli Lilly and Company (NYSE: LLY) announced today that it has elected Jon Moeller as a new member of its board of directors ...
Healthy Returns: Eli Lilly's cholesterol pill impresses in mid-stage trial
The pharmaceutical giant presented mid-stage trial data on the pill, muvalaplin, at the American Heart Association Scientific ...
GlobalData on MSN5d
Eli Lilly reports outcomes from Phase III trial of tirzepatide for HFpEF
The trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.
Eli Lilly and Novo Want to Shake off Ozempic Copycats. Are They Ready to Meet Demand?
The makers of Ozempic and Zepbound are fighting to stop compounded copies of their drugs. But it’s unclear whether they can ...